DK0559413T3 - - Google Patents

Info

Publication number
DK0559413T3
DK0559413T3 DK93301534.9T DK93301534T DK0559413T3 DK 0559413 T3 DK0559413 T3 DK 0559413T3 DK 93301534 T DK93301534 T DK 93301534T DK 0559413 T3 DK0559413 T3 DK 0559413T3
Authority
DK
Denmark
Prior art keywords
meta
treatment
neurodegenerative diseases
nicotine compound
nicotine
Prior art date
Application number
DK93301534.9T
Other languages
Danish (da)
English (en)
Inventor
William S Caldwell
Patrick M Lippiello
Original Assignee
Reynolds Tobacco Co R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reynolds Tobacco Co R filed Critical Reynolds Tobacco Co R
Application granted granted Critical
Publication of DK0559413T3 publication Critical patent/DK0559413T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
DK93301534.9T 1992-03-02 1993-03-01 DK0559413T3 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/844,364 US5212188A (en) 1992-03-02 1992-03-02 Method for treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DK0559413T3 true DK0559413T3 (ja) 1997-03-10

Family

ID=25292523

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93301534.9T DK0559413T3 (ja) 1992-03-02 1993-03-01

Country Status (8)

Country Link
US (1) US5212188A (ja)
EP (1) EP0559413B1 (ja)
JP (1) JPH0624983A (ja)
AT (1) ATE143263T1 (ja)
DE (1) DE69304955T2 (ja)
DK (1) DK0559413T3 (ja)
ES (1) ES2093361T3 (ja)
GR (1) GR3022072T3 (ja)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5731314A (en) * 1995-01-06 1998-03-24 Bencherif; Merouane Pharamceutical compositions for prevention and treatment of tourette's syndrome
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5824692A (en) * 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
AU4610896A (en) * 1995-01-06 1996-07-24 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
ES2318856T4 (es) 1996-04-23 2010-03-03 Targacept, Inc. Composiciones farmaceuticas para la prevencion y el tratamiento de trastornos del sistema nervioso central.
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6166048A (en) * 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6531606B1 (en) * 1997-02-21 2003-03-11 Targacept, Inc. Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US7214686B2 (en) * 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
JP2002504512A (ja) * 1998-02-24 2002-02-12 ウェイク フォレスト ユニバーシティ 慢性の痛みおよび女性特有の痛みを包含する痛みの治療方法
JP2002510619A (ja) * 1998-04-02 2002-04-09 アール・ジェイ・レイノルズ・タバコ・カンパニー 薬剤組成物及びその使用法
US20050131034A1 (en) * 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6262124B1 (en) 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
CA2376061A1 (en) * 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US6890935B2 (en) * 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
FR2810886B1 (fr) * 2000-06-05 2002-12-27 Sanjuan Benito Arranz Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)
US6852741B2 (en) 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
EP1539152A4 (en) * 2002-08-02 2006-10-18 Nutraceutical Dev Corp DEVELOPMENT OF MUSCLE MASS IN A MAMMALIAN
CA2539811A1 (en) * 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
ATE442822T1 (de) * 2004-04-02 2009-10-15 Arterial Remodelling Technolog Stentanordnung auf polymerbasis
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006031856A2 (en) 2004-09-13 2006-03-23 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2133338A1 (en) * 2006-05-09 2009-12-16 AstraZeneca AB Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
CL2007002684A1 (es) * 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
US20100028447A1 (en) * 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
AU2008232453B8 (en) * 2007-04-02 2011-07-21 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
AU2008282205A1 (en) * 2007-07-31 2009-02-05 Astrazeneca Ab Transdermal administration of (2S)-(4E)-N-methyl-5-(3-( 5-isopropoxypyridin)yl)-4-penten-2-amine
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
MX2012013193A (es) 2010-05-20 2012-12-17 Astrazeneca Ab Nuevo proceso para preparar aminas olefinicas sustituidas con arilo.
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US11219627B2 (en) * 2014-05-16 2022-01-11 Synaptec Development Llc Clearance of amyloid beta
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870794A (en) * 1974-02-20 1975-03-11 Foundation For Behavioral Rese Treatment of certain emotional disorders with nicotine compounds
HU179164B (en) * 1979-12-14 1982-08-28 Egyt Gyogyszervegyeszeti Gyar Process for producing cycloalkyl-ethers of alkanolamines
US4442292A (en) * 1981-01-29 1984-04-10 Philip Morris Incorporated Optically active nicotine analogs and process for their preparation
US4578394A (en) * 1984-12-10 1986-03-25 Hoechst-Roussel Pharmaceuticals Incorporated Cholinergic function increasing 3-[N-(pyridyl) carbamoyl]-1,4-dihydropyridines
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4863930A (en) * 1986-12-19 1989-09-05 Adhikary Parimal K Use of substituted 5H-pyrido- and 5H-thiazolo(2',1':2,3)imidazo (4,5-b)indoles as cholinomimetic agents
IL88156A (en) * 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5015741A (en) * 1989-10-03 1991-05-14 Philip Morris Incorporated Nicotine analogs

Also Published As

Publication number Publication date
DE69304955D1 (de) 1996-10-31
DE69304955T2 (de) 1997-04-10
EP0559413A1 (en) 1993-09-08
ATE143263T1 (de) 1996-10-15
GR3022072T3 (en) 1997-03-31
EP0559413B1 (en) 1996-09-25
ES2093361T3 (es) 1996-12-16
JPH0624983A (ja) 1994-02-01
US5212188A (en) 1993-05-18

Similar Documents

Publication Publication Date Title
DK0559413T3 (ja)
TW224942B (ja)
HU9300536D0 (en) Compounds of medical effect
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
GR3019760T3 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
IL103205A0 (en) Compounds for treating leukotriene-related diseases
EP0545511A3 (en) Process for the preparation of mono-n-substituted tetraazamacrocycles
AU2806692A (en) Medicament for the treatment of anxiety
AU1450392A (en) Small peptidic compounds useful for the treatment of glaucoma
ZA886247B (en) Use of a compound for the treatment of schizophrenia
ZA931063B (en) Treatment of glaucoma.
AU4081393A (en) Medicaments for the treatment of anxiety
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
EP0469782A3 (en) Treatment of cataract with prostacyclin compounds
AU5654994A (en) Use of dinaphthalenes compounds as antiproliferative agents
AU5018893A (en) Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
IL106064A (en) Gallium complexes for the treatment of free radical-induced diseases
NZ255753A (en) Use of substituted azaspiranes for psoriasis treatment
AU5532094A (en) Therapeutic agents for the treatment of cachexia
ZA925258B (en) Unit for the treatment of effluent
AU1455992A (en) Organosulphur compounds useful for the treatment of glaucoma
BG96320U (en) Compound for skin treatment
GB9222934D0 (en) Therapeutic compounds
GB9226526D0 (en) Therapeutic compounds
GB9201764D0 (en) The use of a compound for the manufacture of a medicament for the treatment of hiv infection